Archive: Image (Formats)

Home Image

02

Nov2015

Aadi Bioscience Launches its Phase 2 Registration Trial for ABI-009PEComa

0  
Study to be conducted at major cancer centers across the US PACIFIC PALISADES, Calif. (Nov 2, 2015) -- AADi Bioscience, LLC, a clinical stage biopharmaceutical company focused on treating diseases driven by mTOR activation, today announced the initiation of its registration trial for advanced Perivascular Epithelioid Cell tumors (PEComa) with ABI-009, ... Read More
November 2, 2015admin

21

May2014

Pacific pride: Abraxis veteran grooms dormant Celgene drug for success

0  
By Michael Fitzhugh, Staff Writer Aadi LLC. A small new biotech company led by Abraxane (nab-paclitaxel) co-inventor Neil Desai, is in-licensing a once-shelved nanoparticle therapy from Celgene Corp. to develop it for oncology and cardiovascular indications. Celgene acquired the drug, ABI-009, in its 2010 acquisition of Abraxis Bioscience Inc. and retains ... Read More
May 21, 2014admin

20

May2014

AADi Announces Licensing Agreement with Celgene for Nanotechnology-Based Drug Candidate

0  
AADi Initiates NIH Funded Clinical Trial for Patients with Bladder Cancer PACIFIC PALISADES, Calif. (May 20, 2014) -- AADi, LLC, a clinical stage biopharmaceutical company focused on treating diseases uniquely suited for nanotechnology approaches, today announced the inlicensing of ABI-009 from Celgene Corporation (NASDAQ:CELG). ABI-009 is the nanoparticle albumin-bound (nab®) version ... Read More
May 20, 2014admin